cjc 1295 ipamorelin and semaglutide Peptide Therapy | | CJC-1295/Ipamorelin cjc 1295 ipamorelin with semaglutide
Description
The investigators hypothesized that treatment with oral GABA, or a combination of GABA/GAD65-alum, would halt or slow the progression of new onset type 1 diabetes (T1DM) by some/all of the following mechanisms: 1) increasing endogenous insulin secretion, 2) suppression of glucagon release, 3) dampening the T-cell mediated autoimmune process
References Courtney-Martin, G., R.O
Zn-dependent phospholipase A2 contributes to phosphatidylcholine hydrolysis, facilitating micelle formation and intestinal lipid absorption 92,93
10.1186/s12958-018-0406-2 66
